{
    "nct_id": "NCT06483555",
    "official_title": "Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.",
    "inclusion_criteria": "* Written informed consent was obtained to participate in the study and HIPAA authorization for release of personal health information. Subjects is willing and able to comply with study procedures based on the judgment of the investigator.\n* Age â‰¥ 18 years at the time of consent.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1\n* The subject must consent to a mandatory pre-study biopsy if archival tissue is not available or sufficient.\n* Subjects with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial.\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Disease is not measurable according to Response Evaluation Criteria In Solid Tumors Criteria (RECIST) v1.1\n* Not having histological or cytological evidence/confirmation of metastatic pancreatic adenocarcinoma.\n* Prior pancreatic-focused therapy.\n* Brain metastasis diagnosed within the last 4 weeks.",
    "miscellaneous_criteria": ""
}